Previous 10 | Next 10 |
Clarus Therapeutics (CRXT) +18%. AlloVir (ALVR) +18% on FDA regenerative medicine tag for posoleucel to prevent 6 viruses in cell transplant patients. Westwater Resources (WWR) +15% and Alabama Graphite Products break ground on Kellyton processing plant. IceCure Medical (...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Another day of trading is waiting for investors and we’re kicking it off with a look at the biggest pre-market stock movers for Wednesday! Source: Eric Urquhart/Shutterstock.com We’ve got buyout rumors...
The ADRs of Shanghai-based I-Mab (NASDAQ:IMAB) jumped ~18% in the pre-market Wednesday after Bloomberg reported that the clinical-stage biotech company was considering options including a potential sale amid takeover interest from other global drugmakers. I-Mab (IMAB) has lost more ...
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment PR Newswire SHANGHAI and GAITHERSBURG, Md. , March 31, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceut...
I-Mab (IMAB) Q4 2021 Earnings Conference Call March 29, 2022, 08:00 AM ET Company Participants Tyler Ehler - Senior Director of Investor Relations Jingwu Zang - Founder, Chairman and Acting CEO Andrew Zhu - President John Long - Chief Financial Officer Jielun Zhu - Chief Strategy Officer Conf...
I-Mab Biopharma press release (NASDAQ:IMAB): FY Non-GAAP EPS of -$1.54 misses by $0.63. Revenue of $13.8M (-94.2% Y/Y) misses by $70.64M. For further details see: I-Mab Biopharma Non-GAAP EPS of -$1.54 misses by $0.63, revenue of $13.8M misses by $70.64M
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021 PR Newswire Financial results demonstrate strong fundamentals Twenty key clinical milestones achieved year-to-date, including positive data readouts for...
A new US law demands China-based companies with US listings must have their financial reports reviewed by a US auditor. Impact Therapeutics, a Shanghai biopharma, closed a Series D1 funding of undisclosed size to develop its anti-oncology molecules. Five China pharmas have signed ...
I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022 PR Newswire SHANGHAI and GAITHERSBURG, MD , March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committ...
Despite recent regulatory hurdles, the U.S.-listed Chinese pharmaceutical companies have made a comeback in the morning hours on Wednesday. Notable gainers include I-Mab (IMAB +17.9%), BeiGene (BGNE +20.8%), Legend Biotech (LEGN +9.3%), Zai Lab (ZLAB +30.4%), HUTCHMED < > Limited (HCM...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...